Needham raised the firm’s price target on Blueprint Medicines to $97 from $92 and keeps a Buy rating on the shares. The analyst cites the company’s Q4 results as it beat Ayvakit revenue consensus by 14% and provided 2024 guidance implying above-80% growth or 6% above consensus at the midpoint. The 2024 guidance is “achievable” and Needham raises its 2024 Ayvakit estimate closer to the higher end of the guidance range, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines provides 2024 financial guidance
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines price target raised to $70 from $58 at Barclays
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
